rucaparib,abiraterone,enzalutamide
pfizer,astellas,clovis oncology
['brca']
 disappointing to see no benefit in patients with atm mutations but great formbrca1/2
Medical Oncology Fellow @OSUCCC_James | T32 | Aspiring clinical trialist | ICI, cell therapy, & thoracic cancer | s/p @UCDavis @NIH @RWJMS @UTHIMRES